| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Travel | 15 | 2007 | 191 | 1.400 |
Why?
|
| Diarrhea | 16 | 2007 | 722 | 1.310 |
Why?
|
| Escherichia coli Infections | 11 | 2012 | 262 | 1.120 |
Why?
|
| Anti-Bacterial Agents | 21 | 2021 | 3189 | 0.950 |
Why?
|
| Anti-Infective Agents | 11 | 2021 | 465 | 0.790 |
Why?
|
| Immunocompromised Host | 6 | 2021 | 718 | 0.720 |
Why?
|
| Escherichia coli | 13 | 2014 | 1286 | 0.700 |
Why?
|
| Hypersensitivity, Immediate | 1 | 2019 | 23 | 0.650 |
Why?
|
| Skin Tests | 1 | 2019 | 100 | 0.630 |
Why?
|
| Bacteremia | 10 | 2021 | 722 | 0.620 |
Why?
|
| Penicillins | 1 | 2019 | 170 | 0.610 |
Why?
|
| Urogenital Neoplasms | 1 | 2019 | 118 | 0.600 |
Why?
|
| Drug Hypersensitivity | 1 | 2019 | 135 | 0.590 |
Why?
|
| Leukemia | 3 | 2019 | 1719 | 0.450 |
Why?
|
| Pseudomonas aeruginosa | 3 | 2017 | 251 | 0.430 |
Why?
|
| Pseudomonas Infections | 2 | 2017 | 165 | 0.420 |
Why?
|
| Bacterial Toxins | 3 | 2021 | 218 | 0.390 |
Why?
|
| Rifamycins | 4 | 2007 | 32 | 0.390 |
Why?
|
| Gram-Positive Bacterial Infections | 4 | 2016 | 164 | 0.380 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 3 | 2014 | 213 | 0.380 |
Why?
|
| Neoplasms | 17 | 2023 | 15951 | 0.360 |
Why?
|
| Pyomyositis | 1 | 2010 | 8 | 0.350 |
Why?
|
| Enterococcus faecium | 3 | 2016 | 48 | 0.340 |
Why?
|
| Daptomycin | 3 | 2016 | 39 | 0.340 |
Why?
|
| Azithromycin | 3 | 2007 | 79 | 0.330 |
Why?
|
| Communicable Diseases, Emerging | 1 | 2010 | 82 | 0.330 |
Why?
|
| Parainfluenza Virus 2, Human | 1 | 2008 | 4 | 0.320 |
Why?
|
| Drug Resistance, Bacterial | 5 | 2016 | 429 | 0.320 |
Why?
|
| Epiglottitis | 1 | 2008 | 16 | 0.320 |
Why?
|
| Croup | 1 | 2008 | 16 | 0.320 |
Why?
|
| Food Microbiology | 2 | 2009 | 34 | 0.290 |
Why?
|
| Infection Control | 1 | 2008 | 279 | 0.270 |
Why?
|
| Salmonella Infections | 2 | 2021 | 44 | 0.270 |
Why?
|
| Cross Infection | 5 | 2011 | 547 | 0.260 |
Why?
|
| Mexico | 9 | 2009 | 260 | 0.260 |
Why?
|
| Enterocolitis, Pseudomembranous | 2 | 2019 | 109 | 0.260 |
Why?
|
| Enterotoxins | 3 | 2002 | 110 | 0.250 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 5 | 2012 | 134 | 0.230 |
Why?
|
| Respiratory Tract Infections | 1 | 2008 | 405 | 0.230 |
Why?
|
| Escherichia coli Proteins | 4 | 2012 | 368 | 0.230 |
Why?
|
| Bacterial Typing Techniques | 5 | 2012 | 138 | 0.230 |
Why?
|
| Gastrointestinal Diseases | 2 | 2006 | 616 | 0.230 |
Why?
|
| Molecular Epidemiology | 5 | 2012 | 246 | 0.220 |
Why?
|
| Catheterization, Central Venous | 3 | 2017 | 363 | 0.220 |
Why?
|
| Pneumonia, Viral | 3 | 2020 | 701 | 0.210 |
Why?
|
| Disease Reservoirs | 1 | 2002 | 29 | 0.210 |
Why?
|
| DNA Fingerprinting | 4 | 2010 | 180 | 0.200 |
Why?
|
| Bacterial Adhesion | 2 | 2002 | 146 | 0.200 |
Why?
|
| Coronavirus OC43, Human | 1 | 2021 | 13 | 0.190 |
Why?
|
| Convalescence | 1 | 2021 | 23 | 0.190 |
Why?
|
| Common Cold | 1 | 2021 | 35 | 0.190 |
Why?
|
| Immune Reconstitution | 1 | 2021 | 25 | 0.190 |
Why?
|
| Microbial Sensitivity Tests | 8 | 2016 | 1077 | 0.180 |
Why?
|
| Cholera Toxin | 1 | 2000 | 66 | 0.180 |
Why?
|
| Drug Compounding | 1 | 2000 | 73 | 0.180 |
Why?
|
| Lymphopenia | 1 | 2023 | 211 | 0.180 |
Why?
|
| Catheter-Related Infections | 2 | 2017 | 274 | 0.180 |
Why?
|
| Typhoid-Paratyphoid Vaccines | 1 | 2000 | 6 | 0.180 |
Why?
|
| Sweet Syndrome | 1 | 2020 | 35 | 0.180 |
Why?
|
| Antigens, Bacterial | 3 | 2002 | 364 | 0.170 |
Why?
|
| Enterocolitis, Neutropenic | 1 | 2020 | 19 | 0.170 |
Why?
|
| Arthritis, Reactive | 1 | 2000 | 13 | 0.170 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 2 | 2012 | 213 | 0.170 |
Why?
|
| Cluster Analysis | 4 | 2010 | 1076 | 0.170 |
Why?
|
| Carbapenems | 2 | 2017 | 63 | 0.170 |
Why?
|
| Clostridium Infections | 2 | 2021 | 263 | 0.170 |
Why?
|
| Adult | 32 | 2021 | 82042 | 0.170 |
Why?
|
| Humans | 60 | 2023 | 270709 | 0.160 |
Why?
|
| Feces | 8 | 2021 | 852 | 0.160 |
Why?
|
| Betacoronavirus | 2 | 2021 | 514 | 0.160 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2021 | 209 | 0.160 |
Why?
|
| Immunization | 1 | 2000 | 383 | 0.160 |
Why?
|
| Fluoroquinolones | 4 | 2010 | 135 | 0.160 |
Why?
|
| Hematologic Neoplasms | 1 | 2010 | 1956 | 0.150 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 2 | 2012 | 292 | 0.150 |
Why?
|
| Ehrlichiosis | 1 | 1997 | 18 | 0.150 |
Why?
|
| Penicillanic Acid | 1 | 2017 | 22 | 0.150 |
Why?
|
| Disease Outbreaks | 2 | 2011 | 359 | 0.150 |
Why?
|
| Male | 33 | 2021 | 128479 | 0.140 |
Why?
|
| Staphylococcal Infections | 2 | 2013 | 682 | 0.140 |
Why?
|
| Middle Aged | 25 | 2021 | 90517 | 0.140 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 6 | 2021 | 7055 | 0.140 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2020 | 563 | 0.140 |
Why?
|
| Minocycline | 2 | 2009 | 189 | 0.140 |
Why?
|
| Cephalosporins | 1 | 2017 | 173 | 0.130 |
Why?
|
| Bacteriological Techniques | 1 | 2017 | 123 | 0.130 |
Why?
|
| beta-Lactamases | 3 | 2014 | 223 | 0.130 |
Why?
|
| Global Health | 1 | 2001 | 672 | 0.130 |
Why?
|
| Gastroenteritis | 2 | 2011 | 350 | 0.130 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2017 | 164 | 0.130 |
Why?
|
| Enterobacteriaceae | 2 | 2009 | 53 | 0.130 |
Why?
|
| Sodium Hypochlorite | 1 | 2015 | 11 | 0.120 |
Why?
|
| Specimen Handling | 1 | 2017 | 308 | 0.120 |
Why?
|
| Environmental Microbiology | 1 | 2015 | 22 | 0.120 |
Why?
|
| Influenza, Human | 2 | 2012 | 761 | 0.120 |
Why?
|
| Disinfection | 1 | 2015 | 37 | 0.120 |
Why?
|
| Antibodies, Viral | 1 | 2021 | 1217 | 0.120 |
Why?
|
| Genotype | 4 | 2010 | 4246 | 0.120 |
Why?
|
| Aged | 18 | 2021 | 73601 | 0.110 |
Why?
|
| Female | 28 | 2021 | 148873 | 0.110 |
Why?
|
| Aminoglycosides | 1 | 2014 | 232 | 0.110 |
Why?
|
| Cefazolin | 1 | 2013 | 27 | 0.110 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2014 | 169 | 0.110 |
Why?
|
| Ultraviolet Rays | 1 | 2015 | 588 | 0.100 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 623 | 0.100 |
Why?
|
| Infectious Disease Medicine | 1 | 2012 | 21 | 0.100 |
Why?
|
| Practice Management, Medical | 1 | 2012 | 19 | 0.100 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2014 | 308 | 0.100 |
Why?
|
| Polymerase Chain Reaction | 3 | 2012 | 3463 | 0.100 |
Why?
|
| Antiviral Agents | 4 | 2012 | 1243 | 0.100 |
Why?
|
| Bacterial Infections | 2 | 2009 | 510 | 0.100 |
Why?
|
| Quality Improvement | 1 | 2019 | 912 | 0.100 |
Why?
|
| Kidney Transplantation | 1 | 1997 | 750 | 0.100 |
Why?
|
| Virulence Factors | 2 | 2010 | 231 | 0.100 |
Why?
|
| Serratia Infections | 1 | 2011 | 13 | 0.100 |
Why?
|
| Serratia marcescens | 1 | 2011 | 21 | 0.090 |
Why?
|
| Paramyxoviridae Infections | 1 | 2012 | 72 | 0.090 |
Why?
|
| Retrospective Studies | 13 | 2023 | 39968 | 0.090 |
Why?
|
| Drug Contamination | 1 | 2011 | 50 | 0.090 |
Why?
|
| Young Adult | 8 | 2019 | 22241 | 0.090 |
Why?
|
| Cancer Care Facilities | 2 | 2014 | 907 | 0.090 |
Why?
|
| Anti-HIV Agents | 1 | 2014 | 355 | 0.090 |
Why?
|
| Specialization | 1 | 2012 | 128 | 0.090 |
Why?
|
| Immunoglobulin A | 2 | 2002 | 261 | 0.090 |
Why?
|
| Ciprofloxacin | 2 | 2001 | 91 | 0.090 |
Why?
|
| Pandemics | 3 | 2020 | 1607 | 0.090 |
Why?
|
| Medical Oncology | 1 | 2019 | 1464 | 0.090 |
Why?
|
| Interspersed Repetitive Sequences | 1 | 2010 | 35 | 0.090 |
Why?
|
| Vancomycin | 1 | 2012 | 292 | 0.090 |
Why?
|
| Vancomycin Resistance | 1 | 2010 | 61 | 0.090 |
Why?
|
| Double-Blind Method | 4 | 2019 | 2570 | 0.080 |
Why?
|
| Aged, 80 and over | 7 | 2021 | 31113 | 0.080 |
Why?
|
| Staphylococcus aureus | 1 | 2013 | 565 | 0.080 |
Why?
|
| Nasal Lavage Fluid | 1 | 2008 | 18 | 0.080 |
Why?
|
| Lung | 1 | 2020 | 3287 | 0.080 |
Why?
|
| Hoarseness | 1 | 2008 | 26 | 0.080 |
Why?
|
| Texas | 5 | 2020 | 6445 | 0.080 |
Why?
|
| Immunocompetence | 1 | 2008 | 72 | 0.080 |
Why?
|
| Sequence Analysis, DNA | 3 | 2012 | 2560 | 0.080 |
Why?
|
| Caliciviridae Infections | 1 | 2011 | 323 | 0.080 |
Why?
|
| DNA, Bacterial | 2 | 2008 | 604 | 0.080 |
Why?
|
| Vitamin B 6 | 1 | 2008 | 19 | 0.080 |
Why?
|
| Norovirus | 1 | 2011 | 310 | 0.070 |
Why?
|
| Cough | 1 | 2008 | 125 | 0.070 |
Why?
|
| Oxazolidinones | 1 | 2008 | 63 | 0.070 |
Why?
|
| Saliva | 1 | 2008 | 233 | 0.070 |
Why?
|
| Loperamide | 1 | 2007 | 14 | 0.070 |
Why?
|
| Streptomyces | 1 | 2007 | 22 | 0.070 |
Why?
|
| Thiazoles | 1 | 2011 | 727 | 0.070 |
Why?
|
| Acetamides | 1 | 2008 | 109 | 0.070 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2020 | 3155 | 0.070 |
Why?
|
| Hepatitis C | 1 | 2012 | 548 | 0.070 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2020 | 7274 | 0.070 |
Why?
|
| Dysentery | 1 | 2006 | 4 | 0.070 |
Why?
|
| Hematologic Diseases | 1 | 2008 | 255 | 0.070 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 2 | 2010 | 74 | 0.070 |
Why?
|
| Strongyloidiasis | 1 | 2006 | 55 | 0.070 |
Why?
|
| Dacarbazine | 1 | 2008 | 502 | 0.070 |
Why?
|
| Astrocytoma | 1 | 2008 | 325 | 0.060 |
Why?
|
| Diverticulum | 1 | 2006 | 36 | 0.060 |
Why?
|
| Hepatic Encephalopathy | 1 | 2006 | 90 | 0.060 |
Why?
|
| Chronic Disease | 2 | 2008 | 1824 | 0.060 |
Why?
|
| Gastrointestinal Agents | 1 | 2006 | 119 | 0.060 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2008 | 605 | 0.060 |
Why?
|
| Treatment Outcome | 10 | 2012 | 33847 | 0.060 |
Why?
|
| Mycobacterium Infections | 1 | 2004 | 48 | 0.060 |
Why?
|
| Jamaica | 2 | 2001 | 25 | 0.060 |
Why?
|
| Mycobacterium | 1 | 2004 | 60 | 0.060 |
Why?
|
| Chemoprevention | 1 | 2006 | 251 | 0.060 |
Why?
|
| Lymphoma | 2 | 2010 | 1516 | 0.060 |
Why?
|
| HIV Infections | 2 | 2014 | 2154 | 0.060 |
Why?
|
| Adolescent | 11 | 2012 | 32691 | 0.060 |
Why?
|
| Ofloxacin | 1 | 2003 | 43 | 0.060 |
Why?
|
| India | 2 | 2001 | 311 | 0.060 |
Why?
|
| Levofloxacin | 1 | 2003 | 57 | 0.050 |
Why?
|
| Venous Thrombosis | 1 | 2007 | 380 | 0.050 |
Why?
|
| Critical Illness | 1 | 2008 | 734 | 0.050 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2005 | 367 | 0.050 |
Why?
|
| Food Handling | 1 | 2002 | 23 | 0.050 |
Why?
|
| Survivorship | 1 | 2023 | 116 | 0.050 |
Why?
|
| Critical Care | 1 | 2008 | 794 | 0.050 |
Why?
|
| Fatigue | 1 | 2008 | 1290 | 0.050 |
Why?
|
| Endoscopy, Gastrointestinal | 2 | 2020 | 379 | 0.050 |
Why?
|
| Salmonella | 1 | 2021 | 35 | 0.050 |
Why?
|
| Catheters, Indwelling | 1 | 2004 | 382 | 0.050 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2010 | 2454 | 0.050 |
Why?
|
| Food | 1 | 2002 | 151 | 0.050 |
Why?
|
| Infusions, Parenteral | 1 | 2021 | 191 | 0.050 |
Why?
|
| Prevalence | 2 | 2001 | 3392 | 0.050 |
Why?
|
| Cytomegalovirus Infections | 1 | 2005 | 491 | 0.050 |
Why?
|
| Sepsis | 1 | 2007 | 673 | 0.050 |
Why?
|
| Trimethoprim Resistance | 1 | 2001 | 2 | 0.050 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2006 | 358 | 0.050 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2002 | 604 | 0.050 |
Why?
|
| Ribotyping | 1 | 2021 | 50 | 0.050 |
Why?
|
| Methacrylates | 1 | 2000 | 21 | 0.050 |
Why?
|
| Campylobacter Infections | 1 | 2000 | 42 | 0.050 |
Why?
|
| Immunization, Passive | 1 | 2021 | 179 | 0.040 |
Why?
|
| Cross Reactions | 1 | 2021 | 255 | 0.040 |
Why?
|
| Mice, Inbred ICR | 1 | 2000 | 229 | 0.040 |
Why?
|
| HLA-B27 Antigen | 1 | 2000 | 12 | 0.040 |
Why?
|
| Typhoid Fever | 1 | 2000 | 22 | 0.040 |
Why?
|
| Risk Factors | 4 | 2023 | 17850 | 0.040 |
Why?
|
| Enteritis | 1 | 2000 | 67 | 0.040 |
Why?
|
| Stem Cell Transplantation | 1 | 2006 | 1420 | 0.040 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2021 | 509 | 0.040 |
Why?
|
| Fatal Outcome | 2 | 2014 | 818 | 0.040 |
Why?
|
| Antibodies, Bacterial | 1 | 2000 | 402 | 0.040 |
Why?
|
| Prospective Studies | 4 | 2021 | 13407 | 0.040 |
Why?
|
| Oxygen | 1 | 2023 | 786 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2021 | 10409 | 0.040 |
Why?
|
| Outpatients | 1 | 2021 | 458 | 0.040 |
Why?
|
| Hospitals | 2 | 2013 | 482 | 0.040 |
Why?
|
| Transplant Recipients | 1 | 2021 | 335 | 0.040 |
Why?
|
| Aza Compounds | 2 | 2008 | 25 | 0.040 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2010 | 2488 | 0.040 |
Why?
|
| Zoonoses | 1 | 1997 | 47 | 0.040 |
Why?
|
| Ambulatory Care | 1 | 2021 | 592 | 0.030 |
Why?
|
| Granulocytes | 1 | 1997 | 244 | 0.030 |
Why?
|
| Drug Delivery Systems | 1 | 2000 | 663 | 0.030 |
Why?
|
| United States | 4 | 2012 | 15817 | 0.030 |
Why?
|
| Diagnosis, Differential | 3 | 2011 | 4839 | 0.030 |
Why?
|
| Colony Count, Microbial | 1 | 2015 | 159 | 0.030 |
Why?
|
| Microbial Viability | 1 | 2015 | 63 | 0.030 |
Why?
|
| Stenotrophomonas maltophilia | 1 | 2014 | 32 | 0.030 |
Why?
|
| Chemotherapy-Induced Febrile Neutropenia | 1 | 2014 | 33 | 0.030 |
Why?
|
| Quinolines | 2 | 2008 | 402 | 0.030 |
Why?
|
| HIV Integrase Inhibitors | 1 | 2014 | 19 | 0.030 |
Why?
|
| Acinetobacter baumannii | 1 | 2014 | 54 | 0.030 |
Why?
|
| Klebsiella pneumoniae | 1 | 2014 | 101 | 0.030 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2014 | 54 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2021 | 9451 | 0.030 |
Why?
|
| HIV Protease Inhibitors | 1 | 2014 | 74 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2001 | 5759 | 0.030 |
Why?
|
| Ecuador | 1 | 2013 | 15 | 0.030 |
Why?
|
| Colombia | 1 | 2013 | 61 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 2020 | 1436 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2002 | 4494 | 0.030 |
Why?
|
| Drug Prescriptions | 1 | 2014 | 309 | 0.020 |
Why?
|
| Nitro Compounds | 1 | 2011 | 24 | 0.020 |
Why?
|
| Pain | 1 | 2000 | 1701 | 0.020 |
Why?
|
| Brain Neoplasms | 1 | 2008 | 4971 | 0.020 |
Why?
|
| Disease Management | 1 | 2017 | 1092 | 0.020 |
Why?
|
| Syringes | 1 | 2011 | 39 | 0.020 |
Why?
|
| Child, Preschool | 3 | 2012 | 17076 | 0.020 |
Why?
|
| Virulence | 1 | 2012 | 331 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2014 | 1429 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2012 | 6255 | 0.020 |
Why?
|
| Sodium Chloride | 1 | 2011 | 159 | 0.020 |
Why?
|
| Nocardia Infections | 1 | 2010 | 35 | 0.020 |
Why?
|
| Age Factors | 1 | 2020 | 5436 | 0.020 |
Why?
|
| South America | 1 | 2010 | 43 | 0.020 |
Why?
|
| Ceftriaxone | 1 | 2010 | 77 | 0.020 |
Why?
|
| Child | 4 | 2012 | 30563 | 0.020 |
Why?
|
| Secondary Prevention | 1 | 2012 | 311 | 0.020 |
Why?
|
| Enterococcus faecalis | 1 | 2010 | 60 | 0.020 |
Why?
|
| Algorithms | 1 | 2021 | 3905 | 0.020 |
Why?
|
| Latin America | 1 | 2009 | 117 | 0.020 |
Why?
|
| Ice Cream | 1 | 2009 | 3 | 0.020 |
Why?
|
| Restaurants | 1 | 2009 | 23 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2020 | 4392 | 0.020 |
Why?
|
| Phylogeny | 1 | 2012 | 854 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2010 | 590 | 0.020 |
Why?
|
| Focal Infection | 1 | 2008 | 4 | 0.020 |
Why?
|
| Heparin | 1 | 2011 | 343 | 0.020 |
Why?
|
| Hyperlipidemias | 1 | 2010 | 220 | 0.020 |
Why?
|
| Community-Acquired Infections | 1 | 2010 | 286 | 0.020 |
Why?
|
| Linezolid | 1 | 2008 | 71 | 0.020 |
Why?
|
| Pneumonia, Bacterial | 1 | 2009 | 135 | 0.020 |
Why?
|
| Arthritis, Infectious | 1 | 2008 | 75 | 0.020 |
Why?
|
| Graft vs Host Disease | 2 | 2011 | 2811 | 0.020 |
Why?
|
| Vomiting | 1 | 2009 | 359 | 0.020 |
Why?
|
| Nausea | 1 | 2009 | 537 | 0.020 |
Why?
|
| Electronic Health Records | 1 | 2014 | 852 | 0.020 |
Why?
|
| Thiabendazole | 1 | 2006 | 11 | 0.020 |
Why?
|
| Ivermectin | 1 | 2006 | 18 | 0.020 |
Why?
|
| Survival Rate | 1 | 2020 | 12528 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2012 | 2045 | 0.020 |
Why?
|
| Anthelmintics | 1 | 2006 | 69 | 0.020 |
Why?
|
| Infant | 2 | 2012 | 14000 | 0.020 |
Why?
|
| Recurrence | 1 | 2014 | 4878 | 0.020 |
Why?
|
| Hypereosinophilic Syndrome | 1 | 2006 | 86 | 0.020 |
Why?
|
| Drainage | 1 | 2008 | 460 | 0.020 |
Why?
|
| Pneumonia | 1 | 2012 | 791 | 0.020 |
Why?
|
| Case-Control Studies | 2 | 2009 | 6232 | 0.020 |
Why?
|
| Probability | 1 | 2007 | 886 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 3582 | 0.020 |
Why?
|
| Reference Values | 1 | 2007 | 1127 | 0.020 |
Why?
|
| Seizures | 1 | 2010 | 996 | 0.010 |
Why?
|
| Animals | 2 | 2000 | 61350 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2020 | 7788 | 0.010 |
Why?
|
| Bacterial Proteins | 1 | 2010 | 1088 | 0.010 |
Why?
|
| Drug Combinations | 1 | 2005 | 632 | 0.010 |
Why?
|
| Follow-Up Studies | 2 | 2010 | 15274 | 0.010 |
Why?
|
| Coronary Artery Disease | 1 | 2010 | 884 | 0.010 |
Why?
|
| Atrial Fibrillation | 1 | 2010 | 724 | 0.010 |
Why?
|
| Prognosis | 1 | 2020 | 22528 | 0.010 |
Why?
|
| Antibody Formation | 1 | 2002 | 378 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2007 | 2343 | 0.010 |
Why?
|
| Smoking | 1 | 2010 | 2546 | 0.010 |
Why?
|
| Kenya | 1 | 2001 | 50 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2007 | 3534 | 0.010 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2014 | 2903 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2012 | 9278 | 0.010 |
Why?
|
| Drug Resistance, Microbial | 1 | 2001 | 242 | 0.010 |
Why?
|
| Disease Progression | 1 | 2012 | 6880 | 0.010 |
Why?
|
| Incidence | 1 | 2010 | 5814 | 0.010 |
Why?
|
| Occult Blood | 1 | 2000 | 63 | 0.010 |
Why?
|
| Lactoferrin | 1 | 2000 | 88 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 2006 | 3048 | 0.010 |
Why?
|
| Antidiarrheals | 1 | 1999 | 37 | 0.010 |
Why?
|
| Mice | 1 | 2000 | 35420 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2002 | 1503 | 0.010 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2001 | 214 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2007 | 5053 | 0.010 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1999 | 628 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2012 | 8604 | 0.010 |
Why?
|
| Immunoblotting | 1 | 2000 | 887 | 0.010 |
Why?
|
| Kinetics | 1 | 2001 | 2206 | 0.010 |
Why?
|
| Phenotype | 1 | 2009 | 6503 | 0.010 |
Why?
|
| Leukocytes | 1 | 2000 | 420 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2005 | 4315 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2020 | 14639 | 0.010 |
Why?
|
| Intestines | 1 | 2000 | 726 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2007 | 6765 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2000 | 3567 | 0.010 |
Why?
|
| Cell Line | 1 | 2000 | 5313 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 1999 | 5157 | 0.010 |
Why?
|
| Biomarkers | 1 | 2000 | 5049 | 0.000 |
Why?
|